Your browser doesn't support javascript.
loading
Therapeutic efficacy of azithromycin, clarithromycin, minocycline and tosufloxacin against macrolide-resistant and macrolide-sensitive Mycoplasma pneumoniae pneumonia in pediatric patients.
Ishiguro, Nobuhisa; Koseki, Naoko; Kaiho, Miki; Ariga, Tadashi; Kikuta, Hideaki; Togashi, Takehiro; Oba, Koji; Morita, Keisuke; Nagano, Naoko; Nakanishi, Masanori; Hara, Kazuya; Hazama, Kyosuke; Watanabe, Toru; Yamanaka, Tatsuru; Sasaki, Satoshi; Furuyama, Hideto; Shibata, Mutsuo; Shida, Satoru; Ishizaka, Akihito; Tabata, Yuichi; Aoyagi, Hayato; Naito, Hiroyuki; Yoshioka, Mikio; Horino, Atsuko; Kenri, Tsuyoshi.
Afiliação
  • Ishiguro N; Department of Pediatrics, Hokkaido University Graduate School of Medicine, Sapporo, Hokkaido, Japan.
  • Koseki N; Department of Pediatrics, Hokkaido University Graduate School of Medicine, Sapporo, Hokkaido, Japan.
  • Kaiho M; Department of Pediatrics, Hokkaido University Graduate School of Medicine, Sapporo, Hokkaido, Japan.
  • Ariga T; Department of Pediatrics, Hokkaido University Graduate School of Medicine, Sapporo, Hokkaido, Japan.
  • Kikuta H; Pediatric Clinic, Touei Hospital, Sapporo, Hokkaido, Japan.
  • Togashi T; Hokkaido Anti-Tuberculosis Association Sapporo Fukujuji Clinic, Sapporo, Hokkaido, Japan.
  • Oba K; Department of Biostatistics, School of Public Health, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan.
  • Morita K; Interfaculty Initiative in Information Studies, The University of Tokyo, Tokyo, Japan.
  • Nagano N; Department of Pediatrics, Asahikawa Red Cross Hospital, Asahikawa, Hokkaido, Japan.
  • Nakanishi M; Nagano Pediatric Clinic, Asahikawa, Hokkaido, Japan.
  • Hara K; Deparment of Pediatrics, Kushiro Red Cross Hospital, Kushiro, Hokkaido, Japan.
  • Hazama K; Deparment of Pediatrics, Kushiro Red Cross Hospital, Kushiro, Hokkaido, Japan.
  • Watanabe T; Hazama Pediatric Clinic, Muroran, Hokkaido, Japan.
  • Yamanaka T; Watanabe Pediatric Allergy Clinic, Sapporo, Hokkaido, Japan.
  • Sasaki S; Yamanaka Tatsuru Pediatric Clinic, Sapporo, Hokkaido, Japan.
  • Furuyama H; Department of Pediatrics, Aiiku Hospital, Sapporo, Hokkaido, Japan.
  • Shibata M; Deparment of Pediatrics, Japan Community Healthcare Organization Hokkaido Hospital, Sapporo, Hokkaido, Japan.
  • Shida S; Department of Pediatrics, Health Sciences University of Hokkaido, Sapporo, Hokkaido, Japan.
  • Ishizaka A; Deparment of Pediatrics, Ebetsu Municipal Hospital, Ebetsu, Hokkaido, Japan.
  • Tabata Y; Sumiyoshi Kodomo Clinic, Chitose, Hokkaido, Japan.
  • Aoyagi H; Iwamizawa Pediatric and Gynecology Clinic, Iwamizawa, Hokkaido, Japan.
  • Naito H; Deparment of Pediatrics, Obihiro Kyokai Hospital, Obihiro, Hokkaido, Japan.
  • Yoshioka M; Deparment of Pediatrics, Chitose City Hospital, Chitose, Hokkaido, Japan.
  • Horino A; Deparment of Pediatrics, KKR Sapporo Medical Center, Sapporo, Hokkaido, Japan.
  • Kenri T; Department of Bacteriology II, National Institute of Infectious Diseases, Tokyo, Japan.
PLoS One ; 12(3): e0173635, 2017.
Article em En | MEDLINE | ID: mdl-28288170
ABSTRACT

OBJECTIVE:

To clarify therapeutic effects of azithromycin, clarithromycin, minocycline and tosufloxacin against macrolide-resistant Mycoplasma pneumoniae (MRMP) pneumonia and against macrolide-sensitive Mycoplasma pneumoniae (MSMP) pneumonia in pediatric patients.

METHODS:

A prospective, multicenter observational study was conducted from July 2013 to August 2015. The therapeutic effects of azithromycin, clarithromycin, minocycline and tosufloxacin were evaluated in 59 patients with pneumonia caused by MRMP and in 50 patients with pneumonia caused by MSMP. In vitro activities of antimicrobial agents against isolates of Mycoplasma pneumoniae were also measured.

RESULTS:

Mean durations of fever following commencement of treatment in patients infected with MRMP and MSMP were 5.2 and 1.9 days, respectively (log-rank test, P < 0.0001). Among patients infected with MRMP, mean durations of fever were 4.6, 5.5, 1.0 and 7.5 days for patients treated with azithromycin, clarithromycin, minocycline and tosufloxacin, respectively (log-rank test, P < 0.0001). Among patients infected with MSMP, mean durations of fever were 2.5, 1.7, 0.9 and 4.3 days for patients treated with azithromycin, clarithromycin, minocycline and tosufloxacin, respectively (log-rank test, P = 0.0162). The MIC90s of azithromycin and clarithromycin among the 27 isolates of MRMP were 64 and 256 µg/ml, respectively, and those among the 23 isolates of MSMP were <0.000125 and 0.001 µg/ml, respectively. The MIC90s of minocycline and tosufloxacin among the 27 isolates of MRMP were 1.0 and 0.25 µg/ml, respectively, and those among the 23 isolates of MSMP were 1.0 and 0.5 µg/ml, respectively.

CONCLUSION:

Both minocycline and tosufloxacin showed good in vitro activities against MRMP. Minocycline, but not tosufloxacin, shortened the duration of fever in pediatric patients infected with MRMP compared to the duration of fever in patients treated with macrolides.
Assuntos

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Pneumonia por Mycoplasma / Antibacterianos / Mycoplasma pneumoniae Idioma: En Ano de publicação: 2017 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Pneumonia por Mycoplasma / Antibacterianos / Mycoplasma pneumoniae Idioma: En Ano de publicação: 2017 Tipo de documento: Article